AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

AstraZeneca's valuation has been supported by expectations of consistent trial success. The company recently experienced a trial failure in one of its pipeline programs. Analysts have begun reassessing the company's future revenue potential based on this setback. AstraZeneca trades at a premium compared to other large European pharmaceutical companies.

Next story